Physician profile
Shelly Maxwell
NPI 1457035933
$885.03
in general payments reported to CMS, 2019-2025
10 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $636 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $885.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $248.60 | 2024-2025 | Rexulti, Nuedexta |
| Philips North America LLC | $176.43 | 2024 | (Ak6) Vest Therapy, (8874) Incourage |
| Novo Nordisk INC | $174.98 | 2025 | Wegovy |
| Lilly USA, LLC | $118.73 | 2024 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $60.50 | 2024-2025 | Airsupra, Farxiga |
| Astellas Pharma US INC | $27.43 | 2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.35 | 2024 | Caplyta |
| Xeris Pharmaceuticals, INC. | $21.10 | 2025 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $19.56 | 2024 | Gardasil 9, Vaxelis, Capvaxive |
| Glaxosmithkline, LLC. | $15.35 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelly Maxwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.